Cheshire pharmaceutical market Alexion said it’s received approvals from the Japanese government to market its blockbuster drug Soliris for patients with an ultra-rare genetic disorder.
Alexion can now market the drug for treatment of atypical hemolytic uremic syndrome, which caused progressive renal failure and vascular problems through the formation of small blood clots in blood vessels throughout the body.
Soliris is already approved in Japan to treat paroxysmal nocturnal hemoglobinura, a potentially life-threatening condition that impairs the production of blood cells.
